Evidence map›Paper›PMID 30178100›Full record

ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2019

A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future.

Mehrdad Gholamzad, Masoumeh Ebtekar, Mehdi Shafiee Ardestani, Maryam Azimi, Zeinab Mahmodi, Mohammad Javad Mousavi, Saeed Aslani

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2021
    Pooled it
  5. Pooled it
  6. The genetic effect of theBioscience reports · 2018
    Pooled it
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Mehrdad GholamzadDepartment of Microbiology and Immunology, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Khaghani St., Shariati Ave., P.O Box: 19395/1495, Tehran, Iran. mgholamzad@iautmu.ac.ir.
Masoumeh EbtekarDepartment of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Mehdi Shafiee ArdestaniDepartment of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Maryam AzimiDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Zeinab MahmodiDepartment of Microbiology and Immunology, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Khaghani St., Shariati Ave., P.O Box: 19395/1495, Tehran, Iran.
Mohammad Javad MousaviDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Saeed AslaniDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple sclerosis (MS) is a chronic and autoimmune disease of the central nervous system (CNS), mainly characterized by inflammatory demyelination, which manifests as relapses and diffuse damage and brain volume loss, both accounting for neurodegeneration, and therefore, physical disability. MS typically affects young adults and is commonly diagnosed in the early years by acute relapses, which then followed through partial or complete remission period. The clinical course of MS is characterized as four major classifications, including relapsing-remitting (RRMS), primary progressive (PPMS), progressive relapsing (PRMS), and secondary progressive (SPMS). PURPOSE: This review provides comprehensive overview of the current treatments and future innovative approaches in the treatment of MS.

resultsCurrently, there is no definite cure for MS. The treatment of MS has mainly been based on the prescription of immunosuppressive and immune-modulating agents. However, a number of disease-modifying treatments (DMTs) have been designed that reduce the attack rate and delay progression and mainly target inflammation settings in these patients. Although remarkable advancements have occurred in the therapy of MS, the rate of progressive disability and early mortality is still worrisome. Recently, a monoclonal antibody (ocrelizumab) was demonstrated to be beneficial in a clinical trial of primary progressive MS. Furthermore, novel treatment strategies concentrating on the remyelination or neuroprotection are under evaluation.

conclusionsIn spite of prosperous experiences in MS therapy, the future research, hopefully, will bring substantial improvements in the understanding and approaches of MS therapy.

Indexed as

AnimalsBone Marrow TransplantationDrugs, InvestigationalEpigenesis, GeneticHumansMesenchymal Stem Cell TransplantationMultiple SclerosisMyelin SheathT-LymphocytesDrugs, InvestigationalCentral nervous systemDisease-modifying treatmentsMultiple sclerosis

Identifiers

PMID30178100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.